DeepKinomeWeb: a quantitative, panel-level platform for kinase inhibitor screening and selectivity profiling
Open Access
- 29 April 2026
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (W1) , W246-W256
Abstract
Protein kinases are central targets in drug discovery, yet early-stage development of potent and selective inhibitors remains challenging due to high experimental costs and limited interpretability of large-scale screening data. Here, we present DeepKinomeWeb, an integrated web-based platform that transforms competition-based high-throughput screening data into actionable insights for kinase inhibitor prioritization. Built upon our previously validated deep learning regression model, DeepKinome, the platform enables quantitative prediction of kinase–inhibitor binding affinities and provides panel-level visualization of selectivity landscapes, selectivity metric calculations, and integrated structural and physicochemical analyses. Through its user-friendly interface, DeepKinomeWeb supports rational, data-driven decision-making for biologists and medicinal chemists, lowering the barrier to systematic selectivity assessment in kinase inhibitor discovery. DeepKinomeWeb is freely available to all users without any login requirement at https://str.kribb.re.kr/deepkinome.Keywords
Funding Information
- Korea Research Institute of Bioscience and Biotechnology (KGM5362111)
- Korea Research Institute of Bioscience and Biotechnology (KGM1062511)
- Korea Research Institute of Bioscience and Biotechnology (KGM1062511)
- Ministry of Science and ICT, South Korea (RS-2025-16063949)
- Ministry of Science and ICT, South Korea (RS-2024-00440009)
This publication has 33 references indexed in Scilit:
- Overcoming Secondary Mutations of Type II Kinase InhibitorsJournal of Medicinal Chemistry, 2024
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 updatePharmacological Research, 2024
- RCSB Protein Data Bank: Celebrating 50 years of the PDB with new tools for understanding and visualizing biological macromolecules in 3DProtein Science, 2021
- Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLCDrugs, 2021
- Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseJournal of Medicinal Chemistry, 2016
- Comprehensive analysis of kinase inhibitor selectivityNature Biotechnology, 2011
- PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprintsJournal of Computational Chemistry, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005